Min H. Kang - Concepedia

Author

Min H. Kang

Texas Tech University ORCID

Also Known As

H. Kang Min, M H Kang, M. H. Kang, M. Kang, M.H. Kang, Mengqing Kang, Min H Kang, Min H. Kang, Min Hee Kang, Min Kang

255

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Texas Tech University Texas Tech University Health Sciences Center St. Jude Children's Research Hospital Children's Hospital of Philadelphia Center for Cancer Research

About

Min H. Kang is an author at Texas Tech University specializing in medicine, cancer research, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	309
2	Cell Biology	4	4	99
3	Pathology	3	3	55
4	Health Sciences	2	2	99
5	Immunology	2	2	81

Min H. Kang

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Victor Sandor, Susan Bakke, Robert W. Robey, PubMed	2002	509
Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) John M. Maris, Christopher L. Morton, Richard Görlick, Pediatric Blood & Cancer	2010	230
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer John L. Marshall, Naiyer A. Rizvi, John Kauh, Journal of Experimental Therapeutics and Oncology	2002	205
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo Min H. Kang, Yun Hee Kang, Barbara Szymanska, Blood	2007	155
The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma Ashujit Tagde, Harpal Singh, Min H. Kang, Blood Cancer Journal	2014	123
Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation Min H. Kang, Zesheng Wan, Yun Hee Kang, JNCI Journal of the National Cancer Institute	2008	123
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, Clinical Cancer Research	2014	115
Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program E. Anders Kolb, Richard Görlick, Peter J. Houghton, Pediatric Blood & Cancer	2010	108
National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing Min H. Kang, Malcolm A. Smith, Christopher L. Morton, Pediatric Blood & Cancer	2010	99
Initial testing of a monoclonal antibody (IMC‐A12) against IGF‐1R by the pediatric preclinical testing program Peter J. Houghton, Christopher L. Morton, Richard Görlick, Pediatric Blood & Cancer	2010	98

Page 1